Malaria Diagnostics Market by Product Type (Rapid Diagnostic Tests, Microscopy, and Molecular Diagnostic Tests) and End User (Hospital, Clinics, Diagnostic Centers) Global Opportunity Analysis and Industry Forecast, 2019–2026
The global malaria diagnostics market accounted for $728,870 thousand in 2018 and is expected to reach $1,085,106 thousand by 2026, registering a CAGR of 5.1% from 2019 to 2026.
Malaria is an infectious ailment caused by the transmission of Plasmodium parasite. These parasites are transmitted through the bite of infected female Anopheles mosquito. Furthermore, these parasites invade cells of the liver, where they grow and multiply to further invade red blood cells. The mature form of these parasites lead to rupturing of blood cells to form merozoites. In addition, these merozoites further invade other red blood cells, which causes symptoms such as high fever, fatigue, and dizziness. Thus, malaria is highly fatal if left untreated for a long period of time. Tests and procedures which are employed in the identification of malaria are called as malaria diagnostics. Furthermore, there are different types of malaria diagnostics available in the market, which include rapid diagnostic tests, microscopy, and molecular diagnostic tests. In addition, these tests are performed in hospitals, clinics, and diagnostic centers.
The major factor that contributes to the growth of the malaria diagnostics market include rise in prevalence of malaria in developing countries. Furthermore, surge in awareness initiatives by governments and increase in research for new malaria diagnostics are the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is a major factor that restricts the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.
The malaria diagnostics market is studied on the basis of product type, end user, and region to provide a detailed assessment of the market. On the basis of product type, it is segmented into rapid diagnostic tests, microscopy, and molecular diagnostic tests. By end user, it is bifurcated into hospital, clinics, and diagnostic centers. Region wise, it is analyzed across North America (the U.S., and Canada, and Mexico), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
Malaria is an infectious ailment caused by the transmission of Plasmodium parasite. These parasites are transmitted through the bite of infected female Anopheles mosquito. Furthermore, these parasites invade cells of the liver, where they grow and multiply to further invade red blood cells. The mature form of these parasites lead to rupturing of blood cells to form merozoites. In addition, these merozoites further invade other red blood cells, which causes symptoms such as high fever, fatigue, and dizziness. Thus, malaria is highly fatal if left untreated for a long period of time. Tests and procedures which are employed in the identification of malaria are called as malaria diagnostics. Furthermore, there are different types of malaria diagnostics available in the market, which include rapid diagnostic tests, microscopy, and molecular diagnostic tests. In addition, these tests are performed in hospitals, clinics, and diagnostic centers.
The major factor that contributes to the growth of the malaria diagnostics market include rise in prevalence of malaria in developing countries. Furthermore, surge in awareness initiatives by governments and increase in research for new malaria diagnostics are the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is a major factor that restricts the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.
The malaria diagnostics market is studied on the basis of product type, end user, and region to provide a detailed assessment of the market. On the basis of product type, it is segmented into rapid diagnostic tests, microscopy, and molecular diagnostic tests. By end user, it is bifurcated into hospital, clinics, and diagnostic centers. Region wise, it is analyzed across North America (the U.S., and Canada, and Mexico), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global malaria diagnostics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
- By Drug Class
- Rapid Diagnostic Tests
- Microscopy
- Molecular Diagnostic Tests
- By End User
- Hospital
- Clinics
- Diagnostic Centers
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Rest of Europe
- Asia-Pacific
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Africa
- Rest of LAMEA
- List of key players profiled in the report:
- Abbott Laboratories
- Access Bio. Inc.
- Atlas Medical
- Biom?rieux SA
- Bio-Rad Laboratories, Inc.
- Meridian Bioscience Inc
- Novartis AG
- Olympus Corporation
- Premier Medical Corporation Pvt Ltd.
- Siemens AG
- Nikon Corporation
- Thermo Fisher Scientific
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping malaria diagnostics industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of malaria
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in adoption of malaria diagnostics across the globe
3.4.2. Restraint
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: MALARIA DIAGNOSTICS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Rapid Diagnostic Tests
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Microscopy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Molecular Diagnostic Tests
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
CHAPTER 5: MALARIA DIAGNOSTICS MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Clinics
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Diagnostic Centers
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
CHAPTER 6: MALARIA DIAGNOSTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by product type
6.2.2.1.2. U.S. market size and forecast, by end user
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by product type
6.2.2.2.2. Canada market size and forecast, by end user
6.2.3. North America market size and forecast, by product type
6.2.4. North America market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by product type
6.3.2.1.2. Germany market size and forecast, by end user
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by product type
6.3.2.3.2. UK market size and forecast, by end user
6.3.2.4. Rest of Europe
6.3.2.4.1. Rest of Europe market size and forecast, by product type
6.3.2.4.2. Rest of Europe market size and forecast, by end user
6.3.3. Europe market size and forecast, by product type
6.3.4. Europe market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. India
6.4.2.1.1. India market size and forecast, by product type
6.4.2.1.2. India market size and forecast, by end user
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by product type
6.4.2.2.2. China market size and forecast, by end user
6.4.2.3. Rest of Asia-Pacific
6.4.2.3.1. Rest of Asia-Pacific market size and forecast, by product type
6.4.2.3.2. Rest of Asia-Pacific market size and forecast, by end user
6.4.3. Asia-Pacific market size and forecast, by product type
6.4.4. Asia-Pacific market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Arica
6.5.2.1.1. Arica market size and forecast, by product type
6.5.2.1.2. Arica market size and forecast, by end user
6.5.2.2. Rest of LAMEA
6.5.2.2.1. Rest of LAMEA market size and forecast, by product type
6.5.2.2.2. Rest of LAMEA market size and forecast, by end user
6.5.3. LAMEA market size and forecast, by product type
6.5.4. LAMEA market size and forecast, by end user
CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. Access Bio. Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.1. Key strategic moves and developments
7.3. Atlas Medical
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. BIOM?RIEUX SA
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Bio-Rad Laboratories, Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Meridian Bioscience Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. NOVARTIS AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Olympus Corporation
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Premier Medical Corporation Pvt Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.10. SIEMENS
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping malaria diagnostics industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of malaria
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in adoption of malaria diagnostics across the globe
3.4.2. Restraint
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: MALARIA DIAGNOSTICS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Rapid Diagnostic Tests
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Microscopy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Molecular Diagnostic Tests
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
CHAPTER 5: MALARIA DIAGNOSTICS MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Clinics
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Diagnostic Centers
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
CHAPTER 6: MALARIA DIAGNOSTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by product type
6.2.2.1.2. U.S. market size and forecast, by end user
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by product type
6.2.2.2.2. Canada market size and forecast, by end user
6.2.3. North America market size and forecast, by product type
6.2.4. North America market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by product type
6.3.2.1.2. Germany market size and forecast, by end user
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by product type
6.3.2.3.2. UK market size and forecast, by end user
6.3.2.4. Rest of Europe
6.3.2.4.1. Rest of Europe market size and forecast, by product type
6.3.2.4.2. Rest of Europe market size and forecast, by end user
6.3.3. Europe market size and forecast, by product type
6.3.4. Europe market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. India
6.4.2.1.1. India market size and forecast, by product type
6.4.2.1.2. India market size and forecast, by end user
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by product type
6.4.2.2.2. China market size and forecast, by end user
6.4.2.3. Rest of Asia-Pacific
6.4.2.3.1. Rest of Asia-Pacific market size and forecast, by product type
6.4.2.3.2. Rest of Asia-Pacific market size and forecast, by end user
6.4.3. Asia-Pacific market size and forecast, by product type
6.4.4. Asia-Pacific market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Arica
6.5.2.1.1. Arica market size and forecast, by product type
6.5.2.1.2. Arica market size and forecast, by end user
6.5.2.2. Rest of LAMEA
6.5.2.2.1. Rest of LAMEA market size and forecast, by product type
6.5.2.2.2. Rest of LAMEA market size and forecast, by end user
6.5.3. LAMEA market size and forecast, by product type
6.5.4. LAMEA market size and forecast, by end user
CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. Access Bio. Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.1. Key strategic moves and developments
7.3. Atlas Medical
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. BIOM?RIEUX SA
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Bio-Rad Laboratories, Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Meridian Bioscience Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. NOVARTIS AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Olympus Corporation
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Premier Medical Corporation Pvt Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.10. SIEMENS
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL MALARIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2018-2026 ($THOUSAND)
TABLE 02. RAPID DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 03. MICROSCOPY MALARIA DIAGNOSTICS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 04. MOLECULAR DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 05. GLOBAL MALARIA DIAGNOSTICS MARKET, BY END USER, 2018-2026 ($THOUSAND)
TABLE 06. MALARIA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2018–2026 ($THOUSAND)
TABLE 07. MALARIA DIAGNOSTICS MARKET FOR CLINICS, BY REGION, 2018–2026 ($THOUSAND)
TABLE 08. MALARIA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2018–2026 ($THOUSAND)
TABLE 09. MALARIA DIAGNOSTICS MARKET, BY REGION, 2018-2026 ($THOUSAND)
TABLE 10. NORTH AMERICA MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 11. U.S. MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 12. U.S. MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 13. CANADA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 14. CANADA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 15. NORTH AMERICA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 16. NORTH AMERICA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 17. EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 18. GERMANY MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 19. GERMANY MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 20. UK MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 21. UK MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 22. REST OF EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 23. REST OF EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 24. EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 25. EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 26. ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 27. INDIA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 28. INDIA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 29. CHINA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 30. CHINA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 31. REST OF ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 32. REST OF ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 33. ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 34. ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 35. LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 36. ARICA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 37. ARICA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 38. REST OF LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 39. REST OF LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 40. LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 41. LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 42. ABBOTT: COMPANY SNAPSHOT
TABLE 43. ABBOTT: OPERATING SEGMENTS
TABLE 44. ABBOTT: PRODUCT PORTFOLIO
TABLE 45. ACCESSBIO: COMPANY SNAPSHOT
TABLE 46. ACCESSBIO: OPERATING SEGMENTS
TABLE 47. ACCESSBIO: PRODUCT PORTFOLIO
TABLE 48. ATLAS MEDICAL: COMPANY SNAPSHOT
TABLE 49. ATLAS MEDICAL: PRODUCT PORTFOLIO
TABLE 50. BIOM?RIEUX.: COMPANY SNAPSHOT
TABLE 51. BIOM?RIEUX.: OPERATING SEGMENTS
TABLE 52. BIOM?RIEUX: PRODUCT PORTFOLIO
TABLE 53. BIO-RAD: COMPANY SNAPSHOT
TABLE 54. BIO-RAD: OPERATING SEGMENTS
TABLE 55. BIO-RAD: PRODUCT PORTFOLIO:
TABLE 56. MERIDIAN: COMPANY SNAPSHOT
TABLE 57. MERIDIAN: OPERATING SEGMENTS
TABLE 58. MERIDIAN: PRODUCT PORTFOLIO
TABLE 59. NOVARTIS: COMPANY SNAPSHOT
TABLE 60. NOVARTIS: OPERATING SEGMENTS
TABLE 61. NOVARTIS: PRODUCT PORTFOLIO
TABLE 62. OLYMPUS: COMPANY SNAPSHOT
TABLE 63. OLYMPUS: OPERATING SEGMENTS
TABLE 64. OLYMPUS: PRODUCT PORTFOLIO
TABLE 65. PREMIER MEDICAL CORPORATION: COMPANY SNAPSHOT
TABLE 66. PREMIER MEDICAL CORPORATION: OPERATING SEGMENTS
TABLE 67. PREMIER MEDICAL CORPORATION: PRODUCT PORTFOLIO
TABLE 68. SIEMENS: COMPANY SNAPSHOT
TABLE 69. SIEMENS: OPERATING SEGMENTS
TABLE 70. SIEMENS: PRODUCT PORTFOLIO
TABLE 01. GLOBAL MALARIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2018-2026 ($THOUSAND)
TABLE 02. RAPID DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 03. MICROSCOPY MALARIA DIAGNOSTICS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 04. MOLECULAR DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 05. GLOBAL MALARIA DIAGNOSTICS MARKET, BY END USER, 2018-2026 ($THOUSAND)
TABLE 06. MALARIA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2018–2026 ($THOUSAND)
TABLE 07. MALARIA DIAGNOSTICS MARKET FOR CLINICS, BY REGION, 2018–2026 ($THOUSAND)
TABLE 08. MALARIA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2018–2026 ($THOUSAND)
TABLE 09. MALARIA DIAGNOSTICS MARKET, BY REGION, 2018-2026 ($THOUSAND)
TABLE 10. NORTH AMERICA MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 11. U.S. MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 12. U.S. MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 13. CANADA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 14. CANADA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 15. NORTH AMERICA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 16. NORTH AMERICA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 17. EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 18. GERMANY MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 19. GERMANY MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 20. UK MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 21. UK MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 22. REST OF EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 23. REST OF EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 24. EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 25. EUROPE MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 26. ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 27. INDIA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 28. INDIA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 29. CHINA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 30. CHINA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 31. REST OF ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 32. REST OF ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 33. ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 34. ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 35. LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 36. ARICA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 37. ARICA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 38. REST OF LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($THOUSAND)
TABLE 39. REST OF LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026 ($THOUSAND)
TABLE 40. LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($THOUSAND)
TABLE 41. LAMEA MALARIA DIAGNOSTICS MARKET REVENUE, BY END USER, 2019–2026($THOUSAND)
TABLE 42. ABBOTT: COMPANY SNAPSHOT
TABLE 43. ABBOTT: OPERATING SEGMENTS
TABLE 44. ABBOTT: PRODUCT PORTFOLIO
TABLE 45. ACCESSBIO: COMPANY SNAPSHOT
TABLE 46. ACCESSBIO: OPERATING SEGMENTS
TABLE 47. ACCESSBIO: PRODUCT PORTFOLIO
TABLE 48. ATLAS MEDICAL: COMPANY SNAPSHOT
TABLE 49. ATLAS MEDICAL: PRODUCT PORTFOLIO
TABLE 50. BIOM?RIEUX.: COMPANY SNAPSHOT
TABLE 51. BIOM?RIEUX.: OPERATING SEGMENTS
TABLE 52. BIOM?RIEUX: PRODUCT PORTFOLIO
TABLE 53. BIO-RAD: COMPANY SNAPSHOT
TABLE 54. BIO-RAD: OPERATING SEGMENTS
TABLE 55. BIO-RAD: PRODUCT PORTFOLIO:
TABLE 56. MERIDIAN: COMPANY SNAPSHOT
TABLE 57. MERIDIAN: OPERATING SEGMENTS
TABLE 58. MERIDIAN: PRODUCT PORTFOLIO
TABLE 59. NOVARTIS: COMPANY SNAPSHOT
TABLE 60. NOVARTIS: OPERATING SEGMENTS
TABLE 61. NOVARTIS: PRODUCT PORTFOLIO
TABLE 62. OLYMPUS: COMPANY SNAPSHOT
TABLE 63. OLYMPUS: OPERATING SEGMENTS
TABLE 64. OLYMPUS: PRODUCT PORTFOLIO
TABLE 65. PREMIER MEDICAL CORPORATION: COMPANY SNAPSHOT
TABLE 66. PREMIER MEDICAL CORPORATION: OPERATING SEGMENTS
TABLE 67. PREMIER MEDICAL CORPORATION: PRODUCT PORTFOLIO
TABLE 68. SIEMENS: COMPANY SNAPSHOT
TABLE 69. SIEMENS: OPERATING SEGMENTS
TABLE 70. SIEMENS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL MALARIA DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, MALARIA DIAGNOSTICS MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF RAPID DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MICROSCOPY MALARIA DIAGNOSTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MALARIA DIAGNOSTICS MARKET FOR HSOPITALS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MALARIA DIAGNOSTICS MARKET FOR CLINICS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MALARIA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. U.S. MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 17. CANADA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 18. GERMANY MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 19. UK MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 20. REST OF EUROPE MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 21. INDIA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 22. CHINA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 23. REST OF ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 24. ARICA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 25. REST OF LAMEA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 26. ABBOTT: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 27. ABBOTT: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 28. ABBOTT: REVENUE SHARE BY REGION, 2018(%)
FIGURE 29. BIOM?RIEUX: NET SALES, 2018–2019 ($THOUSAND)
FIGURE 30. BIO-RAD: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 31. BIO-RAD: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 32. BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 33. MERIDIAN: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 34. MERIDIAN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 35. MERIDIAN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 36. NOVARTIS: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 37. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39. OLYMPUS CORPORATION: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 40. OLYMPUS: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 41. OLYMPUS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42. NET SALES, 2016–2018 ($THOUSAND)
FIGURE 43. SIEMENS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. SIEMENS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 01. GLOBAL MALARIA DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, MALARIA DIAGNOSTICS MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF RAPID DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MICROSCOPY MALARIA DIAGNOSTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTIC TESTS MALARIA DIAGNOSTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MALARIA DIAGNOSTICS MARKET FOR HSOPITALS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MALARIA DIAGNOSTICS MARKET FOR CLINICS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MALARIA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. U.S. MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 17. CANADA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 18. GERMANY MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 19. UK MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 20. REST OF EUROPE MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 21. INDIA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 22. CHINA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 23. REST OF ASIA-PACIFIC MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 24. ARICA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 25. REST OF LAMEA MALARIA DIAGNOSTICS MARKET, 2018-2026 ($THOUSAND)
FIGURE 26. ABBOTT: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 27. ABBOTT: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 28. ABBOTT: REVENUE SHARE BY REGION, 2018(%)
FIGURE 29. BIOM?RIEUX: NET SALES, 2018–2019 ($THOUSAND)
FIGURE 30. BIO-RAD: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 31. BIO-RAD: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 32. BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 33. MERIDIAN: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 34. MERIDIAN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 35. MERIDIAN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 36. NOVARTIS: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 37. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39. OLYMPUS CORPORATION: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 40. OLYMPUS: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 41. OLYMPUS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42. NET SALES, 2016–2018 ($THOUSAND)
FIGURE 43. SIEMENS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. SIEMENS: REVENUE SHARE BY REGION, 2018 (%)
